Company Profile:

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Recent News:

On April 28, 2021, the company announced that it has dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfilzomib and dexamethasone.

As of December 31, 2020, Trillium had cash and cash equivalents and marketable securities of $291.2 million, compared to $22.7 million at December 31, 2019.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

TRIL’s strengths can be seen in its strong profitability compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, the MACD is trying to cross back up and the RSI stands at 45.76 with positive bias. We rate Trillium Therapeutics Inc. (TRIL) a STRONG BUY.